The Immune Response Corporation Offers 2,400,000 Shares of Its Common
Stock
CARLSBAD, Calif., Jul 12, 2000 /PRNewswire via COMTEX/ -- The Immune Response
Corporation (Nasdaq: IMNR) announced today that it has filed a supplement to its
previously filed shelf registration statement with the Securities and Exchange
Commission (SEC) for a public offering of 2,400,000 shares of its common stock
(plus up to 360,000 additional shares to cover over-allotments, if any). The
shares are being offered through First Security Van Kasper and Gruntal & Co.,
L.L.C.
The Company plans to use substantially all of the net proceeds from the sale of
the common stock to further its REMUNE(TM) manufacturing process scale-up, for
product development, for working capital and other general corporate purposes.
The common stock is offered for sale only by means of the related prospectus and
prospectus supplement, meeting the requirements of Section 10 of the Securities
Act of 1933, a copy of which may be obtained from First Security Van Kasper, 600
California Street, San Francisco, CA 94108-2704, and Gruntal & Co., L.L.C., One
Liberty Plaza - 17th Floor, New York, NY 10006-1487. |
